Loading clinical trials...

Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE) | Clinical Trials | Clareo Health

RECRUITING

Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)

NCT03792854•Ludwig-Maximilians - University of Munich

View on ClinicalTrials.gov

Summary

Detailed Description

Observational study to evaluate longitudinal quality of life according to standardized EORTC questionaires as well as functional outcome, oncological outcome and toxicity in patients treated with definitive chemoradiation for anal cancer. Qol will be evaluated by standardized EORTC questionaires QLQ C30 and QLQ CR29. Acute and late toxicity will be assessed according to CTCAE 4.03. Oncological outcome will be assessed with regard to local and distant control, patterns of recurrence, freedom from treatment failure and overall survival. Correlations of physicians- and patients-assessed functional outcomes are planned.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•histologically proven anal cancer without distant metastases
•indication for definitive chemoradiation therapy based on multidisciplinary evaluation
•age \>=18 years
•written informed consent
•ability to answer the standardized questionaires according to the treating physician

Exclusion Criteria

•age \< 18 years
•prior systemic therapy with regard to anal cancer
•distant metastases
•second malignancy

Locations (1)

Department of Radiation Oncology, University Hospital, LMU Munich

Munich, Bavaria, Germany

Key Dates

Start Date

December 1, 2018

Primary Completion Date

December 1, 2021

Completion Date

December 1, 2026

Last Updated

January 3, 2019

Enrollment

100

ESTIMATED participants

Conditions

Anal CancerQuality of LifeChemoradiation

Interventions

EORTC QLQ C30

OTHER

EORTC QLQ CR29

OTHER

Contacts

Falk Roeder, MD

CONTACT

+49894400 falk.roeder@t-online.de

Sabine Gerum, MD

CONTACT

+49894400 sabine.gerum@med.uni-muenchen.de

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

NCT04929028

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 3, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Prospective Observational Trial to Evaluate Quality of Life After Definitive Chemoradiation in Patients With Anal Cancer (LANACARE)

Inclusion Criteria

Exclusion Criteria

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

"Erectile Function After PCI in MI and Non-MI Patients"

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

PRophylaxis Against Early VENTilator-associated Infections in Acute Brain Injury

Predictive Factors for Functional and Quality of Life Decline in Patients >65 Years With a Gastrointestinal Tract Cancer Diagnosis Taken to Curative Resectable Surgery

The PREGNANT (Pregnant Resident Empowerment, GuidaNce, and Advocacy iN Training) Coaching Project